The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

30 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
23
Synthesis and carbonic anhydrase isoenzymes I, II, IX, and XII inhibitory effects of dimethoxybromophenol derivatives incorporating cyclopropane moieties.EBI
Ataturk University
23
Synthesis of donepezil-based multifunctional agents for the treatment of Alzheimer's disease.EBI
Ataturk University
11
N-Acylsulfonamides strongly inhibit human carbonic anhydrase isoenzymes I and II.EBI
Ataturk University
9
Novel sulfamides as potential carbonic anhydrase isoenzymes inhibitors.EBI
Ataturk University
16
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols and their derivatives including natural products: vidalol B.EBI
Ataturk University
12
In vitro inhibition of human erythrocyte glutathione reductase by some new organic nitrates.EBI
Ataturk University
5
A novel and one-pot synthesis of new 1-tosyl pyrrol-2-one derivatives and analysis of carbonic anhydrase inhibitory potencies.EBI
Ataturk University
12
NO-releasing esters show carbonic anhydrase inhibitory action against human isoforms I and II.EBI
Ataturk University
11
Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.EBI
Ataturk University
10
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.EBI
Ataturk University
24
Comprehensive study on potent and selective carbonic anhydrase inhibitors: Synthesis, bioactivities and molecular modelling studies of 4-(3-(2-arylidenehydrazine-1-carbonyl)-5-(thiophen-2-yl)-1H-pyrazole-1-yl) benzenesulfonamides.EBI
Ataturk University
1
Design, synthesis and biological evaluation of 3,5-diaryl isoxazole derivatives as potential anticancer agents.EBI
Ataturk University
8
Synthesis and carbonic anhydrase inhibitory properties of sulfamides structurally related to dopamine.EBI
Ataturk University
667
Heterocyclic inhibitors of glutaminaseBDB
Calithera Biosciences
38
Compounds as cannabinoid receptor ligandsBDB
Abbvie
7
Pyrazine derivatives and use as PI3K inhibitorsBDB
Merck Serono
33
Identification of stabilizers of multimeric proteinsBDB
The Leland Stanford Junior University
180
Oxazine derivatives and their use in the treatment of neurological disordersBDB
Novartis
50
Triazole compounds that modulate HSP90 activityBDB
Synta Pharmaceuticals
312
Imidazopyridine derivatives as inhibitors of receptor tyrosine kinasesBDB
Astex Therapeutics
13
Synthesis of (glycopyranosyl-triazolyl)-purines and their inhibitory activities against protein tyrosine phosphatase 1B (PTP1B).BDB
East China University of Science and Technology
343
Inhibitors of PI3 kinase and/or mTORBDB
Amgen
422
AminopyrazoloquinazolinesBDB
Boehringer Ingelheim International
25
Inhibitors of PI3 kinaseBDB
Amgen
2
GSK-3 inhibitorsBDB
Neuropharma
14
Prolylcarboxypeptidase inhibitorsBDB
Merck Sharp & Dohme
13
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.BDB
Merck Frosst Centre For Therapeutic Research
18
Cloning and characterization of the rat 5-HT5B receptor. Evidence that the 5-HT5B receptor couples to a G protein in mammalian cell membranes.BDB
University of Heidelberg Zmbh
14
Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.BDB
Abbott Laboratories